Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00780351|
Recruitment Status : Completed
First Posted : October 27, 2008
Last Update Posted : October 23, 2009
- Sustained low efficiency daily hemodiafiltration(SLEDD-f) is a kind of renal replacement therapy with high-flux dialyser membrane (helixone).
- The pore size of helixone is larger than most antibiotics, and vancomycin is supposed to be removed during dialysis.
- Our study wants to find the amount of vancomycin removed during SLEDD-f, and try to find the most appropriate dose regimen for this kind of patients.
|Condition or disease||Intervention/treatment|
|Acute Renal Failure||Device: sustained low efficiency daily hemodiafiltration (SLEDD-f)|
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||Pharmacokinetics and Dosing of Vancomycin in Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)|
|Study Start Date :||October 2008|
|Actual Study Completion Date :||August 2009|
Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
Device: sustained low efficiency daily hemodiafiltration (SLEDD-f)
vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
- The amount of vancomycin removed during one course of SLEDD-f [ Time Frame: 8 hr (during one course of SLEDD-f) ]
- The pharmacokinetics and dosing regimen of vancomycin in patients on SLEDD-f. [ Time Frame: 26 hr ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00780351
|National Taiwan University Hospital|
|Principal Investigator:||Fe-Lin L Wu, MSCP, Ph.D.||School of pharmacy, Graduate institute of clinical pharmacy, Department of Pharmacy of National Taiwan University Hospital, College of Medicine, National Taiwan University|
|Principal Investigator:||Wen-Je Ko, MD, PhD||Department of Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University|